4th Quarter - Report
TODD STRATEGY GROUP for GILEAD SCIENCES, INC.
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies. Supply Chain. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus). Reauthorization of the Prescription Drug User Fee Act and related issue
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL | — |
| JEFF LUCAS | — |
| DANIEL M TODD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.